Dr Smith said that PFL/BPL had elected to try dry heating of an existing product, 8CRV. In the proposal he recognised "our late start." Read more about Dr Smith said that PFL/BPL had elected to try dry heating of an existing product, 8CRV. In the proposal he recognised "our late start."
Dr Smith was concerned that the few blood product recipients who had not already been infected with hepatitis might be engaged in testing other products to establish, for licensing authorities considering the grant of licences in respect of those products, whether they did, indeed, reduce non-A non-B Hepatitis as claimed. Read more about Dr Smith was concerned that the few blood product recipients who had not already been infected with hepatitis might be engaged in testing other products to establish, for licensing authorities considering the grant of licences in respect of those products, whether they did, indeed, reduce non-A non-B Hepatitis as claimed.
Dr Smith proposed to make a special preparation of Factor 8 which would be subjected to dry heat (8CRV). Read more about Dr Smith proposed to make a special preparation of Factor 8 which would be subjected to dry heat (8CRV).
The draft proof of evidence of Dr Richard Lane expressed that "NANBH causes increasing concern, less on account of its acute effects (although deaths have been reported) than because of its association with chronic active hepatitis in later life", and that AIDS was "not yet proven to be of viral origin, but this is strongly presumed". Read more about The draft proof of evidence of Dr Richard Lane expressed that "NANBH causes increasing concern, less on account of its acute effects (although deaths have been reported) than because of its association with chronic active hepatitis in later life", and that AIDS was "not yet proven to be of viral origin, but this is strongly presumed".
Dr Smith visited PFC in Scotland and discussed research and development in respect of coagulation factors, and put forward to Dr Lane a "Proposal to Develop a 'Hepatitis-Safe' Factor VIII Concentrate". Read more about Dr Smith visited PFC in Scotland and discussed research and development in respect of coagulation factors, and put forward to Dr Lane a "Proposal to Develop a 'Hepatitis-Safe' Factor VIII Concentrate".
A number of other possibilities for reducing the risk of hepatitis were canvassed by BPL 1981. Read more about A number of other possibilities for reducing the risk of hepatitis were canvassed by BPL 1981.
A paper was produced by the Research and Development department of BPL, which noted that heating albumin products for such a period in the presence of a stabiliser had a "good record in the elimination of hepatitis virus infectivity" and that "If similar stabilisers can be established for coagulation factor products then heat inactivation will become the treatment of choice." Read more about A paper was produced by the Research and Development department of BPL, which noted that heating albumin products for such a period in the presence of a stabiliser had a "good record in the elimination of hepatitis virus infectivity" and that "If similar stabilisers can be established for coagulation factor products then heat inactivation will become the treatment of choice."
Dr Lane recorded that he proposed to the CBLA Scientific and Technical Committee in the spring of 1981 that a research project into the development of coagulation factor concentrates with reduced risk of hepatitis transmission was an appropriate project for central funding. Read more about Dr Lane recorded that he proposed to the CBLA Scientific and Technical Committee in the spring of 1981 that a research project into the development of coagulation factor concentrates with reduced risk of hepatitis transmission was an appropriate project for central funding.
Dr Lane reported to the Scientific and Technical Committee of the Central Blood Laboratories Authority during the next month that "a research project into the development of coagulation factor concentrates with reduced risk of hepatitis transmission, was an appropriate case for central funding." Read more about Dr Lane reported to the Scientific and Technical Committee of the Central Blood Laboratories Authority during the next month that "a research project into the development of coagulation factor concentrates with reduced risk of hepatitis transmission, was an appropriate case for central funding."
Dr James Smith wrote: "The significance of a product demonstrably free of hepatitis risk cannot be ignored and it is essential that BPL/PFL be well placed to take advantage of such developments." Read more about Dr James Smith wrote: "The significance of a product demonstrably free of hepatitis risk cannot be ignored and it is essential that BPL/PFL be well placed to take advantage of such developments."